Investigational drug · Phase 3
MG1111
Also called: BARICELA, Barycela inj.
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Varicella, Varicella (Chickenpox), Chickenpox Vaccine.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "MG1111"
First trial start
2022
Jul 5, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MG1111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Varicella
- Varicella (Chickenpox)
- Chickenpox Vaccine
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "MG1111" as an intervention, largest first.
- A Study of MG1111 in Healthy ChildrenPivotal-lookingCompleted
Green Cross CorporationIndustry
NCT03375502 · 814 participants · Start Nov 26, 2016 · Primary completion Jan 29, 2019
Drug: Varicella Vaccine · For: Healthy Children
Sites: Banpo-dong, South Korea
- A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 YearsPivotal-lookingRecruiting
GC Biopharma CorpIndustry
NCT07054099 · 474 participants (planned) · Start Mar 17, 2026 · Primary completion Aug 2027
Drug: MG1111 (Barycela inj.); VARIVAX™ · For: Varicella (Chickenpox); Chickenpox Vaccine
Sites: Khon Kaen, Thailand
- An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 YearsStatus unknown
GC Biopharma CorpIndustry
NCT05664152 · 250 participants (planned) · Start Feb 2023 · Primary completion Apr 2023
Drug: MG1111 · For: Varicella Zoster Virus Infection
- Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella VaccinationPivotal-lookingRecruiting
Green Cross CorporationIndustry
NCT05422508 · 230 participants (planned) · Start Jul 5, 2022 · Primary completion Jun 2025
Drug: MG1111 (BARICELA); VARIVAX and 1 more · For: Varicella
Sites: Ansan, South Korea
Green Cross CorporationIndustry
NCT02367638 · 39 participants (planned) · Start Mar 2015 · Primary completion Jul 2015
Drug: MG1111; VARIVAX · For: Varicella (Chicken Pox)
Newest research
PubMed records naming it or its code names, newest first.
- Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus.
Hwang JY, Kim Y, Lee KM, et al. · Hum Vaccin Immunother 2023
- Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study.
Choi UY, Kim KH, Lee J, et al. · Vaccine 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.